How will you decide between neoadjuvant CheckMate 816 approach vs adjuvant IMpower010 approach in a fit patient with EGFR negative resectable Stage II-III NSCLC patient with PD-L1 high expression tumor?

In general, our multi-d group believes in neoadj approach to shrink the tumor and apply systemic therapy at the earliest time point. Most neoadj approaches also continue the I/O after surgery if there is a good response. It may be that patients with a complete path response or without ctDNA may not ...